Edition:
United States

MyoKardia Inc (MYOK.OQ)

MYOK.OQ on NASDAQ Stock Exchange Global Select Market

55.41USD
19 Oct 2018
Change (% chg)

$-0.24 (-0.43%)
Prev Close
$55.65
Open
$55.66
Day's High
$56.81
Day's Low
$55.08
Volume
68,913
Avg. Vol
110,938
52-wk High
$67.15
52-wk Low
$32.85

Latest Key Developments (Source: Significant Developments)

MyoKardia Announces Pricing Of Public Offering Of Common Stock
Tuesday, 22 May 2018 08:05pm EDT 

May 22 (Reuters) - MyoKardia Inc ::MYOKARDIA ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 3.75 MILLION COMMON SHARES PRICED AT $49.00PER SHARE.  Full Article

MyoKardia Says Offering 3.75 Mln Common Shares
Monday, 21 May 2018 04:01pm EDT 

May 21 (Reuters) - MyoKardia Inc ::MYOKARDIA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.SAYS OFFERING 3.75 MILLION COMMON SHARES.MYOKARDIA - ANTICIPATES USING NET PROCEEDS FROM OFFERING TO FUND RESEARCH AND DEVELOPMENT ACTIVITIES FOR ITS DEVELOPMENT PROGRAMS, AMONG OTHERS.  Full Article

Myokardia Announces Appointment Of Taylor C. Harris As Chief Financial Officer
Wednesday, 4 Apr 2018 08:30am EDT 

April 4 (Reuters) - Myokardia Inc ::MYOKARDIA ANNOUNCES APPOINTMENT OF TAYLOR C. HARRIS AS CHIEF FINANCIAL OFFICER.HARRIS MOST RECENTLY SERVED AS CFO OF ZELTIQ AESTHETICS UNTIL THAT COMPANY'S ACQUISITION BY ALLERGAN PLC.JAKE BAUER ‍HAS BEEN PROMOTED TO ROLE OF CHIEF BUSINESS OFFICER ​.  Full Article

Myokardia Reports Q4 Loss Per Share Of $0.21
Thursday, 8 Mar 2018 04:03pm EST 

March 8 (Reuters) - Myokardia Inc ::MYOKARDIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.21.Q4 EARNINGS PER SHARE VIEW $-0.41 -- THOMSON REUTERS I/B/E/S.MYOKARDIA - EXPECTS THAT CASH, CASH EQUIVALENTS & INVESTMENTS AS OF DEC 31, 2017 WILL FUND ANTICIPATED OPERATING EXPENSES & CAPEX REQUIREMENTS INTO 2020.  Full Article

Myokardia Announces Positive Results From Phase 2 Pioneer-Hcm Study Of Mavacamten
Thursday, 8 Mar 2018 04:02pm EST 

March 8 (Reuters) - Myokardia Inc ::MYOKARDIA ANNOUNCES POSITIVE RESULTS FROM LOW-DOSE COHORT OF PHASE 2 PIONEER-HCM STUDY OF MAVACAMTEN IN SYMPTOMATIC, OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY PATIENTS.MYOKARDIA INC - STUDY MET PRIMARY ENDPOINT AND KEY SECONDARY ENDPOINTS WITH STATISTICAL SIGNIFICANCE.MYOKARDIA INC - STUDY RESULTS INFORM PHASE 3 EXPLORER-HCM DOSING; FIRST PATIENT PLANNED FOR Q2 2018.  Full Article

MyoKardia Inc reports Q3 loss per share $0.42
Thursday, 2 Nov 2017 04:02pm EDT 

Nov 2 (Reuters) - MyoKardia Inc :MyoKardia Inc reports third quarter 2017 financial results and operational progress.Q3 loss per share $0.42.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.MyoKardia Inc - ‍collaboration and license revenue was $5.6 million during three months ended September 30, 2017, compared with $3.6 million​.MyoKardia Inc - ‍expects cash, cash equivalents, among others, to enable funding anticipated operating expenses and capex requirements at least into 2020​.  Full Article

MyoKardia expects to initiate next trial of MYK-491 in DCM patients by year-end
Wednesday, 27 Sep 2017 07:30am EDT 

Sept 27 (Reuters) - MyoKardia Inc :MyoKardia provides update on MYK-491 clinical progress.MyoKardia Inc - ‍next trial of MYK-491 in DCM patients expected to initiate by year-end​.MyoKardia Inc says ‍MyoKardia intends to initiate a single ascending dose trial of MYK-491 in symptomatic DCM patients before year-end​.MyoKardia Inc - ‍topline data of Myk-491 expected by early 2018​.  Full Article

MyoKardia announces pricing of public offering of common stock
Tuesday, 8 Aug 2017 09:13pm EDT 

Aug 9 (Reuters) - MyoKardia Inc -:MyoKardia announces pricing of public offering of common stock.Says public offering of 3.50 million common shares priced at $35.50per share.  Full Article

MyoKardia announces proposed public offering of common stock
Monday, 7 Aug 2017 04:01pm EDT 

Aug 7 (Reuters) - Myokardia Inc :Commenced a proposed underwritten public offering of 3.5 million shares of its common stock.  Full Article

Myokardia reports Q2 loss per share $0.41
Monday, 7 Aug 2017 07:19am EDT 

Aug 7 (Reuters) - Myokardia Inc :Myokardia reports second quarter 2017 financial results and operational progress.Qtrly loss per share $0.41.Q2 earnings per share view $-0.35 -- Thomson Reuters I/B/E/S.Myokardia - sees cash, cash equivalents, investments as of June 30 enabling funding of anticipated operating expenses, capex requirements at least into 2019.  Full Article